Peringatan Keamanan

Oral, rat: LD50 = >5 gm/kg. Amphotericin B overdoses can result in cardio-respiratory arrest.

Amphotericin B

DB00681

small molecule approved investigational

Deskripsi

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

Struktur Molekul 2D

Berat 924.079
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours.
Volume Distribusi -
Klirens (Clearance) * 39 +/- 22 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day at Day 1] * 17 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day 3-20 days later] * 51 +/- 44 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day at Day 1] * 22 +/- 15 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day 3-20 days later] * 21 +/- 14 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day at Day 1] * 11 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day 3-20 days later]

Absorpsi

Bioavailability is 100% for intravenous infusion.

Metabolisme

Exclusively renal

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1202 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Amphotericin B is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Amphotericin B is combined with Levodopa.
Risperidone Amphotericin B may increase the hypotensive activities of Risperidone.
Cyclosporine Amphotericin B may increase the nephrotoxic activities of Cyclosporine.
Voriconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.
Ketoconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.
Miconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.
Itraconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.
Posaconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.
Abafungin The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Abafungin.
Ravuconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ravuconazole.
Isavuconazonium The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isavuconazonium.
Isavuconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isavuconazole.
Albaconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Albaconazole.
Bifonazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole.
Levoketoconazole The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Levoketoconazole.
Digoxin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.
Deslanoside The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.
Ouabain The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.
Digitoxin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.
Oleandrin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Oleandrin.
Cymarin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Cymarin.
Proscillaridin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Proscillaridin.
Metildigoxin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metildigoxin.
Lanatoside C The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lanatoside C.
Gitoformate The risk or severity of adverse effects can be increased when Amphotericin B is combined with Gitoformate.
Acetyldigoxin The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigoxin.
Peruvoside The risk or severity of adverse effects can be increased when Amphotericin B is combined with Peruvoside.
Flunisolide The risk or severity of hypokalemia can be increased when Flunisolide is combined with Amphotericin B.
Beclomethasone dipropionate The risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Amphotericin B.
Betamethasone The risk or severity of hypokalemia can be increased when Betamethasone is combined with Amphotericin B.
Fluticasone propionate The risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Amphotericin B.
Fluocinolone acetonide The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Amphotericin B.
Triamcinolone The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Amphotericin B.
Prednisone The risk or severity of hypokalemia can be increased when Prednisone is combined with Amphotericin B.
Fludrocortisone The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Amphotericin B.
Hydrocortisone The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Amphotericin B.
Prednisolone The risk or severity of hypokalemia can be increased when Prednisolone is combined with Amphotericin B.
Methylprednisolone The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Amphotericin B.
Trilostane The risk or severity of hypokalemia can be increased when Trilostane is combined with Amphotericin B.
Budesonide The risk or severity of hypokalemia can be increased when Budesonide is combined with Amphotericin B.
Dexamethasone The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Amphotericin B.
Corticotropin The risk or severity of hypokalemia can be increased when Corticotropin is combined with Amphotericin B.
Cortisone acetate The risk or severity of hypokalemia can be increased when Cortisone acetate is combined with Amphotericin B.
Paramethasone The risk or severity of hypokalemia can be increased when Paramethasone is combined with Amphotericin B.
Ciclesonide The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Amphotericin B.
Aldosterone The risk or severity of hypokalemia can be increased when Aldosterone is combined with Amphotericin B.
Fluticasone furoate The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Amphotericin B.
Fluprednidene The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Amphotericin B.
Tixocortol The risk or severity of hypokalemia can be increased when Tixocortol is combined with Amphotericin B.
Fluprednisolone The risk or severity of hypokalemia can be increased when Fluprednisolone is combined with Amphotericin B.
Meprednisone The risk or severity of hypokalemia can be increased when Meprednisone is combined with Amphotericin B.
Dexamethasone isonicotinate The risk or severity of hypokalemia can be increased when Dexamethasone isonicotinate is combined with Amphotericin B.
Melengestrol The risk or severity of hypokalemia can be increased when Melengestrol is combined with Amphotericin B.
Deflazacort The risk or severity of hypokalemia can be increased when Deflazacort is combined with Amphotericin B.
Cortivazol The risk or severity of hypokalemia can be increased when Cortivazol is combined with Amphotericin B.
Prednylidene The risk or severity of hypokalemia can be increased when Prednylidene is combined with Amphotericin B.
Fluocortin The risk or severity of hypokalemia can be increased when Fluocortin is combined with Amphotericin B.
Fluperolone The risk or severity of hypokalemia can be increased when Fluperolone is combined with Amphotericin B.
Cloprednol The risk or severity of hypokalemia can be increased when Cloprednol is combined with Amphotericin B.
Fluclorolone The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Amphotericin B.
Fluticasone The risk or severity of hypokalemia can be increased when Fluticasone is combined with Amphotericin B.
Mometasone furoate The risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Amphotericin B.
Hydrocortisone acetate The risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Amphotericin B.
Hydrocortisone cypionate The risk or severity of hypokalemia can be increased when Hydrocortisone cypionate is combined with Amphotericin B.
Hydrocortisone succinate The risk or severity of hypokalemia can be increased when Hydrocortisone succinate is combined with Amphotericin B.
Prednisolone phosphate The risk or severity of hypokalemia can be increased when Prednisolone phosphate is combined with Amphotericin B.
Prednisolone hemisuccinate The risk or severity of hypokalemia can be increased when Prednisolone hemisuccinate is combined with Amphotericin B.
Methylprednisolone hemisuccinate The risk or severity of hypokalemia can be increased when Methylprednisolone hemisuccinate is combined with Amphotericin B.
Prednisone acetate The risk or severity of hypokalemia can be increased when Prednisone acetate is combined with Amphotericin B.
Clocortolone acetate The risk or severity of hypokalemia can be increased when Clocortolone acetate is combined with Amphotericin B.
Melengestrol acetate The risk or severity of hypokalemia can be increased when Melengestrol acetate is combined with Amphotericin B.
Betamethasone phosphate The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Amphotericin B.
Cortisone The risk or severity of hypokalemia can be increased when Cortisone is combined with Amphotericin B.
Clobetasol propionate The risk or severity of hypokalemia can be increased when Clobetasol propionate is combined with Amphotericin B.
Fluocinonide The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Amphotericin B.
Hydrocortisone butyrate The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Amphotericin B.
Desoximetasone The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Amphotericin B.
Mometasone The risk or severity of hypokalemia can be increased when Mometasone is combined with Amphotericin B.
Fluocortolone The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Amphotericin B.
Prednisolone acetate The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Amphotericin B.
Fluorometholone The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Amphotericin B.
Difluocortolone The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Amphotericin B.
Flumethasone The risk or severity of hypokalemia can be increased when Flumethasone is combined with Amphotericin B.
Methylprednisolone aceponate The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Amphotericin B.
Foscarnet The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amphotericin B.
Tenofovir disoproxil Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Amphotericin B may increase the nephrotoxic activities of Tenofovir.
Colistimethate Amphotericin B may increase the nephrotoxic activities of Colistimethate.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amphotericin B.
Aripiprazole Aripiprazole may increase the hypotensive activities of Amphotericin B.
Aripiprazole lauroxil Aripiprazole lauroxil may increase the hypotensive activities of Amphotericin B.
Nicorandil Nicorandil may increase the hypotensive activities of Amphotericin B.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Amphotericin B.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Amphotericin B.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amphotericin B.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Amphotericin B.

Target Protein

Ergosterol

Referensi & Sumber

Synthesis reference: Frank Sipos, "Process for producing the methyl ester of amphotericin B." U.S. Patent US4035567, issued March, 1976.

Contoh Produk & Brand

Produk: 17 • International brands: 9
Produk
  • Abelcet
    Injection • - • Intravenous • US • Approved
  • Abelcet
    Suspension • 5 mg / mL • Intravenous • Canada • Approved
  • AmBisome
    Injection, powder, lyophilized, for solution • 50 mg/12.5mL • Intravenous • US • Approved
  • AmBisome
    Powder, for solution • 50 mg / vial • Intravenous • Canada • Approved
  • Amphotec
    Injection, lipid complex • 50 mg/50mg • Intravenous • US • Approved
  • Amphotec
    Injection, lipid complex • 100 mg/100mg • Intravenous • US • Approved
  • Amphotec
    Injection, lipid complex • 50 mg/10mL • Intravenous • US • Approved
  • Amphotec
    Injection, lipid complex • 100 mg/20mL • Intravenous • US • Approved
Menampilkan 8 dari 17 produk.
International Brands
  • Abelect — Cephalon
  • Ampho-Moronal — Dermapharm
  • Amphocil — Alza
  • Amphocin — Pfizer
  • Amphotericin — Bristol-Myers Squibb
  • Fungilin — Sigma
  • Fungisome
  • Fungizone Intravenous — Bristol-Myers Squibb
  • Halizon — Fuji Yakuhin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul